BioCentury
ARTICLE | Clinical News

QGC001: Phase Ia data

November 5, 2012 8:00 AM UTC

A double-blind, placebo-controlled, French Phase Ia trial in 56 healthy male volunteers showed that single ascending-doses of 10-1,250 mg oral QGC001 were well tolerated. A Phase Ib trial is evaluatin...